Pashtoon Kasi/LinkedIn
Jan 29, 2025, 07:43
Pashtoon Kasi: Immunotherapy’s Potential in Refractory Patients with Liver Metastases
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post by Marwan G. Fakih, on X:
“GI25 this is a study.
FOLFOX – 3B
BOT
BAL
BEV
Immunotherapy alone may not work for those with active liver metastases. But in a refractory patient population, this is encouraging to see.
Need more ideas for patients with liver metastases.”
Quoting Marwan G. Fakih‘s post:
‘GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the patients had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT.’
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 07:39
Jan 29, 2025, 07:38
Jan 29, 2025, 07:35
Jan 29, 2025, 07:28
Jan 29, 2025, 06:21
Jan 28, 2025, 20:25
Jan 28, 2025, 19:39